PDCD1 and cancer: Anti-PD-1/PD-L1 immunotherapy strengthens antitumor immunity by “releasing the brakes” for immune suppression in the tumor microenvironment and has exhibited inspiring efficacy in various cancer types, resulting in FDA approval and wide clinical application (2–4).